CD34 expression in adult acute lymphoblastic leukemia

Area of Science:

• Hematology
• Immunology
• Oncology

Background:

• CD34 is a pluripotent stem cell antigen.
• Its role in acute lymphoblastic leukemia (ALL) prognosis requires further elucidation.
• Understanding CD34 expression can refine patient stratification and treatment strategies.

Purpose of the Study:

• To evaluate the prognostic significance of CD34 antigen expression in adult de novo ALL.
• To correlate CD34 expression with clinical, hematological, and immunophenotypic features.
• To assess the impact of CD34 positivity on treatment response and survival.

Main Methods:

• Immunophenotypic analysis of CD34 expression on diagnostic bone marrow samples from 45 adult de novo ALL patients.
• Comparison of clinical and hematological parameters between CD34-positive and CD34-negative groups.
• Assessment of complete remission rates and overall survival.

Main Results:

• CD34 positivity was observed in 24 out of 45 patients.
• CD34-positive ALL patients were older, had more lymphoid organ involvement, and higher LDH levels.
• The CD34-positive group exhibited a 'null' immunophenotype, VLA-4/VLA-5 integrin expression, and frequent association with myeloid antigens (CD13, CD33) or P-gp/MDR-1.
• Complete remission rates were significantly lower (45%) in CD34-positive patients versus CD34-negative patients (95%).
• Median survival was shorter in CD34-positive patients (6.6 months) compared to CD34-negative patients (13.5 months).

Conclusions:

• CD34 expression in adult de novo ALL is associated with distinct clinical and immunophenotypic characteristics.
• CD34 positivity predicts a poor prognosis, characterized by lower remission rates and shorter survival.
• These findings suggest CD34 antigen evaluation is valuable for prognostic assessment in ALL, similar to its role in acute myeloid leukemia (AML).